Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
5.00
-0.12 (-2.34%)
At close: Apr 28, 2026, 4:00 PM EDT
5.10
+0.10 (2.00%)
After-hours: Apr 28, 2026, 6:04 PM EDT
Opus Genetics Revenue
In the year 2025, Opus Genetics had annual revenue of $14.20M with 29.15% growth. Opus Genetics had revenue of $3.87M in the quarter ending December 31, 2025, a decrease of -10.16%.
Revenue (ttm)
$14.20M
Revenue Growth
+29.15%
P/S Ratio
25.15
Revenue / Employee
$507,000
Employees
28
Market Cap
357.01M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Puma Biotechnology | 228.37M |
| Enanta Pharmaceuticals | 66.98M |
| X4 Pharmaceuticals | 35.11M |
| Surrozen | 3.48M |
| Compass Therapeutics | 850.00K |
| Silence Therapeutics | 559.00K |
| YD Bio | 510.36K |
| vTv Therapeutics | 17.00K |
IRD News
- 1 day ago - Opus Genetics to Participate in Leading Medical Conferences in May 2026 - GlobeNewsWire
- 18 days ago - Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting - GlobeNewsWire
- 22 days ago - Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital - GlobeNewsWire
- 5 weeks ago - Opus Genetics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026 - GlobeNewsWire
- 7 weeks ago - Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Opus Genetics to Present at Upcoming Investor Conferences in March 2026 - GlobeNewsWire
- 2 months ago - Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting - GlobeNewsWire
- 2 months ago - Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia - GlobeNewsWire